For 20+ years, most believed we had only a few hours after a stroke to provide treatment—but the RapidAI founders were never satisfied with that thinking. They theorized that stroke evolution was highly variable, the conventional short treatment windows could be upended, and far more people with cerebrovascular disorders could be saved. They recognized that technology was the limiting factor even after an early NIH-funded, multicenter trial showed important advancements. The founders developed the Rapid platform to address this need.
President & CEO
Dr. Greg Albers
Co-founder & Scientific Lead
Co-founder & Technical Lead
Rapid, its cerebrovascular imaging software platform powered by artificial intelligence, currently includes:
- Rapid ICH
Automatically triages non-contrast CT scans to quickly identify suspected intracranial hemorrhages
- Rapid ASPECTS
Automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury; the first and only neuro-imaging device which has been shown to improve reader diagnosis under the FDA’s CADx (Computer-Assisted Diagnostic) classification
- Rapid CTA and Rapid LVO
Automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of suspected large vessel occlusions (LVOs)
- Rapid CTP
Fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time; the only clinically validated software with an FDA indication to aid in the selection of patients for acute stroke therapy
- Rapid MRI
Fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival
- Rapid Mobile App
Securely access RapidAI results and preview source files from multiple sites, receive notifications, and communicate about patient care, anytime, anywhere
A cloud-based computational platform providing comprehensive cerebral aneurysm management—automating the entire workflow from initial assessment to growth monitoring and treatment planning
- Rapid Web App
Conveniently view new case information and preview Rapid results using Google Chrome or Microsoft Edge on any desktop or laptop—saving you and your patients precious time
- RapidAI Insights
A suite of reports and analytics on Rapid scan, treatment and outcomes data that help hospital clinical, executive and IT teams make informed decisions to standardize stroke care processes and optimize operational efficiencies
Step of the Radiologist Journey
RapidAI launches Rapid ICH to quickly notify physicians of possible intracranial hemorrhages, Rapid LVO for identification of suspected large vessel occlusions, and RapidAI Insights—an analytics offering tracking Rapid scan, treatment, and outcomes data. RapidAI hits a major milestone with over 1 million recorded scans.
Rapid ICH launches worldwide, using artificial intelligence to quickly notify physicians of possible intracranial hemorrhage.
The EXTEND trial doubles the treatment window for intravenous tPA using Rapid CTP and Rapid MRI.
Based on the DAWN and DEFUSE 3 clinical trials that used Rapid imaging to select stroke patients for late-window treatment, the American Heart and American Stroke associations revise guidelines, extending the treatment window for acute stroke patients from 6 to 24 hours.
The Rapid platform achieves CE Mark certification, paving the way for use in the European Union.
Rapid platform selected as the exclusive imaging selection method for the late-window trials, DAWN and DEFUSE 3.
American Heart Association guidelines endorse thrombectomy as a new standard of care for stroke patients who can be treated up to 6 hours after onset. Rapid platform installed in more than 100 stroke centers.
SWIFT PRIME and EXTEND-IA trials document the highest favorable outcome rates ever obtained in a stroke trial and validate the use of Rapid CTP to select patients for thrombectomy within 6 hours of symptom onset.
Rapid CTP and Rapid MRI receive FDA clearance, allowing the platform to be used in hospitals throughout the U.S.
Dr. Albers and Dr. Bammer co-found the company iSchemaView (now named RapidAI™) and purchase the rights to Rapid technology from Stanford University.
Rapid MRI software installed in eight US and one European center for the NIH-sponsored DEFUSE 2 study.
Dr. Greg Albers and Dr. Roland Bammer develop Rapid technology, the first fully automated image processing platform, at Stanford University.
Vision for the Future
WHAT IS YOUR
PRODUCT DEVELOPMENT ROADMAP?
In 2020, RapidAI expanded its scope from ischemic stroke to hemorrhagic stroke and comprehensive aneurysm management.
HOW DO YOU SEE THE FUTURE
OF THE AI ECOSYSTEM?
Already a key component in advanced medical imaging, AI will continue to expand its use across serious conditions and stages of diagnosis and treatment.
WHAT IS YOUR ROLE IN IT?
The Rapid platform is the de facto standard in cerebrovascular imaging and the company is the trailblazer in utilizing machine learning and artificial intelligence to empower clinicians to make faster, more accurate diagnostic and treatment decisions—ultimately improving patient outcomes. RapidAI will continue to expand AI’s use from improving the capabilities of readers of scans to expanded use in tracking and treating.